BRAIN Biotech AG Company Presentation | Specialty Enzymes, BioIncubator & Growth Strategy
Investor Snapshot
- COMPANY
- BRAIN Biotech AG
- FORMAT
- Company Presentation
- SPEAKER
- Michael Schneiders
- ROLE
- Investor Relations
- DURATION
- 13:26
- PUBLISHED
- August 2026
- LANGUAGE
- English
In 60 Seconds
BRAIN Biotech AG is an industrial biotechnology company focused on specialty enzymes, microorganisms and biological solutions for food, life sciences and industrial applications.
The company has two pillars: BRAINBiocatalysts, its core enzyme business, and BRAINBioIncubator, which houses high-potential biotechnology projects.
BRAIN generated around €45 million in FY2024/25 revenue, with €4.4 million adjusted EBITDA, and has capabilities across the full enzyme value chain—from discovery and protein engineering to fermentation, production and distribution.
The opportunity is significant. The global industrial enzyme market is expected to grow 6–7% annually, while BRAIN currently holds mostly single-digit market shares, leaving substantial room for expansion.
Its BioIncubator projects also offer major upside. Deals with Royalty Pharma and Akribion Therapeutics could generate up to €138 million and €92 million, respectively, plus royalties.
Overall, BRAIN’s strategy is to combine its integrated technology platform, growing enzyme markets and monetisation of breakthrough innovations to achieve profitable growth and become a top-ten global enzyme company.
August 18, 2026
13:26 
BRAIN Biotech AG Company Presentation: Key Takeaways
BRAIN Biotech AG Company Presentation
In this Company Presentation on seat11a, Michael Schneiders, CFO of BRAIN Biotech AG, presents the company’s business model, biotechnology platform, growth opportunities and long-term strategy to become one of the world’s leading specialty enzyme companies.
Industrial Biotechnology and Specialty Enzyme Solutions
BRAIN Biotech is an industrial biotechnology company developing specialty enzymes, microorganisms and biological solutions for applications across food, life sciences and industrial markets. The company uses cells, microorganisms and biomolecules to develop biological processes that can operate under milder conditions, use renewable raw materials and reduce waste and emissions compared with conventional industrial processes.
BRAINBiocatalysts and BRAINBioIncubator
The company operates through two complementary pillars. BRAINBiocatalysts comprises the core specialty enzyme business, while BRAINBioIncubator contains selected high-innovation projects and participations with additional commercialisation potential. In FY 2024/25, BRAIN generated approximately €45.4 million in annual revenue and €4.4 million in adjusted EBITDA, complemented by approximately €4.2 million of recurring revenues.
Integrated Enzyme Value Chain and Biotechnology Platform
A key strength is BRAIN’s position across the entire enzyme value chain. Its capabilities extend from biological discovery, protein engineering and microbial strain development through fermentation, scale-up and industrial production to formulation, sales and distribution. BRAIN combines these capabilities across three business models: proprietary enzyme products and ingredients, contract research and contract manufacturing. This integrated structure enables the company to provide customised biological solutions while developing long-term relationships with industrial customers.
Global Industrial Enzyme Market and Growth Opportunities
The market opportunity is substantial. BRAIN estimates that the global market for industrial enzyme applications will expand by around 6–7% annually through 2030/2035, supported by structural trends including sustainability, resilience, changing food consumption and new pharmaceutical applications. Within BRAINBiocatalysts alone, management identifies more than €2 billion in accessible enzyme markets across applications including dairy, baking, brewing, fruit juice and wine, starch processing, life sciences and other specialties. Current BRAIN market shares remain mostly in the single digits, providing significant room for expansion.
BRAINBioIncubator and Biotechnology Innovation Projects
The second pillar, BRAINBioIncubator, provides additional value creation opportunities from breakthrough biotechnology projects. Its portfolio spans areas including fermented food and beverages, biological gold recovery, natural antimicrobials, chronic wound treatment, genome-editing technologies and pharmaceutical royalties. Management is increasingly partnering these projects with specialised external companies to share development costs, reduce risk and accelerate commercialisation.
Royalty Pharma and Akribion Therapeutics Monetisation
The monetisation strategy has already produced tangible results. BRAIN signed an agreement with Royalty Pharma to monetise royalty rights related to deucrictibant, with potential proceeds of up to €138 million. It also licensed G-dase E technology for therapeutic applications to Akribion Therapeutics, with potential milestone payments of up to approximately €92 million plus royalties on future net sales. These transactions demonstrate the potential to convert innovation projects into financial value while allowing BRAIN to concentrate resources on its core industrial biotechnology activities.
Long-Term Strategy to Become a Top-Ten Global Enzyme Company
BRAIN’s strategic ambition is to achieve profitable growth in specialty enzymes and become one of the top-ten global enzyme companies. The combination of growing addressable markets, an integrated technology platform, relatively low existing market shares and the commercialisation potential of BioIncubator projects forms the foundation of the company’s long-term growth strategy.
- Biotechnology in the Spotlight as a Key Technology of the Future
- Biotechnology: Efficient Technologies for Health, Nutrition & Resilience
- The Market for Industrial Applications of Enzymes Keeps Constantly Growing
- Successful Specialty Player in Research, Development and Production of Enzyme
- BRAIN Biotech Acts as a Solutions Provider Across the Entire Enzyme Value Chain
- BRAINBiocatalysts – Offering Specialty Products and Tailor-made Solutions
- Innovation and Growth has Several Drivers
- BRAINBiocatalysts – Significant Room for Growth in Well Over €2bn Accessible Market
- BRAIN BIOINCUBATOR – Creating Highly Innovative Partnered Solutions and Attractive Value
- BRAIN BIOINCUBATOR – the Commercialization Phase has Already Started
- Why You Should Think About Investing into BRAIN Biotech
This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/
Continuing the Journey: More Presentations
Discover Additional Elevator Pitches
(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG
Unlock the insights of top publicly listed companies with seat11a.com